An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Brivanib alaninate (INN/USAN) also known as BMS-582664 is an investigational, anti-tumorigenic drug for oral administration. The drug is being developed by Bristol-Myers Squibb for the treatment of hepatocellular carcinoma or HCC (also called malignant hepatoma), the most common type of liver cancer. Brivanib is no longer in active development. Brivanib alaninate is a multitargeted tyrosine kinase inhibitor (as is sorafenib).

Property Value
dbo:abstract
  • Brivanib alaninate (INN/USAN) also known as BMS-582664 is an investigational, anti-tumorigenic drug for oral administration. The drug is being developed by Bristol-Myers Squibb for the treatment of hepatocellular carcinoma or HCC (also called malignant hepatoma), the most common type of liver cancer. Brivanib is no longer in active development. Brivanib alaninate is a multitargeted tyrosine kinase inhibitor (as is sorafenib). Brivanib alaninate also inhibits VEGFR and fibroblast growth factor receptors (FGFR), which is known to play a major role in the etiopathogenesis of HCC. To date, brivanib alaninate has been investigated in 29 studies, including more than 4,000 patients around the world. (en)
dbo:casNumber
  • 649735-63-7
dbo:chEBI
  • 167656
dbo:chEMBL
  • 270995
dbo:fdaUniiCode
  • U2Y5OFN795
dbo:pubchem
  • 11154925
dbo:thumbnail
dbo:wikiPageExternalLink
dbo:wikiPageID
  • 34793637 (xsd:integer)
dbo:wikiPageLength
  • 11987 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1100173024 (xsd:integer)
dbo:wikiPageWikiLink
dbp:atcPrefix
  • none (en)
dbp:c
  • 22 (xsd:integer)
dbp:casNumber
  • 649735 (xsd:integer)
dbp:chebi
  • 167656 (xsd:integer)
dbp:chembl
  • 270995 (xsd:integer)
dbp:chemspiderid
  • 9330033 (xsd:integer)
dbp:f
  • 1 (xsd:integer)
dbp:h
  • 24 (xsd:integer)
dbp:iupacName
  • --1-propan-2-yl 2-aminopropanoate (en)
dbp:iupharLigand
  • 8097 (xsd:integer)
dbp:legalUs
  • IND (en)
dbp:n
  • 5 (xsd:integer)
dbp:o
  • 4 (xsd:integer)
dbp:pubchem
  • 11154925 (xsd:integer)
dbp:routesOfAdministration
  • Oral (en)
dbp:smiles
  • CC1=CC2=CC=CCOC3=NC=NN4C3=CC (en)
dbp:stdinchi
  • 1 (xsd:integer)
dbp:stdinchikey
  • LTEJRLHKIYCEOX-OCCSQVGLSA-N (en)
dbp:unii
  • U2Y5OFN795 (en)
dbp:wikiPageUsesTemplate
dcterms:subject
gold:hypernym
rdf:type
rdfs:comment
  • Brivanib alaninate (INN/USAN) also known as BMS-582664 is an investigational, anti-tumorigenic drug for oral administration. The drug is being developed by Bristol-Myers Squibb for the treatment of hepatocellular carcinoma or HCC (also called malignant hepatoma), the most common type of liver cancer. Brivanib is no longer in active development. Brivanib alaninate is a multitargeted tyrosine kinase inhibitor (as is sorafenib). (en)
rdfs:label
  • Brivanib alaninate (en)
owl:sameAs
prov:wasDerivedFrom
foaf:depiction
foaf:isPrimaryTopicOf
is dbo:wikiPageRedirects of
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License